This concept has been illustrated through the effective combination of carboplatin with mirvetuximab soravtansine (targeting folate receptor α with DM4), anetumab ravtansine (targeting mesothelin with DM4), or luveltamab tazevibulin (targeting folate receptor α with SC239) in ovarian cancer preclinically [7–9]. This evidence concerns the gene MSLN and ovarian cancer.